Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-22
2007-05-22
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000, C435S007100, C435S325000, C424S009100
Reexamination Certificate
active
10456947
ABSTRACT:
The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent that inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
REFERENCES:
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 2003/0027260 (2003-02-01), Goddard et al.
patent: 2003/0032090 (2003-02-01), Hardiman et al.
patent: 2003/0032674 (2003-02-01), Hwang
patent: 2003/0060410 (2003-03-01), Tracey et al.
patent: 2003/0144201 (2003-07-01), Tracey et al.
patent: 2004/0005316 (2004-01-01), Tracey et al.
patent: 10082788 (1998-03-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/20756 (1999-04-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 00/47104 (2000-08-01), None
patent: WO 00/75358 (2000-12-01), None
patent: WO 01/72993 (2001-04-01), None
patent: WO 01/36488 (2001-05-01), None
patent: WO 01/55386 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/90151 (2001-11-01), None
patent: WO 01/90151 (2001-11-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/089743 (2002-11-01), None
patent: WO 02/090520 (2002-11-01), None
patent: WO 02/090520 (2002-11-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 03/022296 (2003-03-01), None
Kim, J., et al., “Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses,”J. Immunol., 169(3):1535-1541 (2002).
Matsuguchi, T., et al., “Gene Expression of Toll-Like Receptor 2, But Not Toll-Like Receptor 4, Is Induced by LPS and Inflammatory Cytokines in Mouse Macrophages,”J. Immunol., 165(10): 5767-5772 (2000).
Jones, B. W., et al., “Different Toll-Like Receptor Agonists Induce Distinct Macrophage Responses,”J. Leukoc. Biol., 69(6):1036-1044 (2001).
Means, T. K., et al., “Human Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis,”J. Immunol., 3920-3927 (1999).
Abraham, E., et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation,”J. Immunol., 165:2950-2954 (2000).
Andersson, U., et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes,”J. Exp. Med., 192(4):565-570 (2000).
Bustin, M. “Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins,”Trends Biochem. Sci., 26(3):152-153 (2001).
Degryse, B., et al., “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells,”J. Cell Biol., 152(6):1197-1206 (2001).
Wang, H., et al., “HMG-1 as a Late Mediator of Endotoxin Lethality in Mice,”Science, 285:248-251 (1999).
Wang, H., et al., “Proinflammatory Cytokines (Tumor Necrosis Factor and Interleukin 1) Stimulate Release of High Mobility Group Protein-1 by Pituicytes,”Surgery, 126:389-392 (1999).
Bianchi, M. E., et al., “The DNA Binding Site of HMG1 Protein Is Composed of Two Similar Segments (HMG Boxes), Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins,”EMBO J., 11(3): 1055-1063 (1992).
Aderem, A. and Ulevitch, R.J., “Toll-Like Receptors in the Induction of the Innate Immune Response,”Nature, 406:782-787 (2000).
Beutler, E., et al., “Synergy Between TLR2 and TLR4: A Safety Mechanism,”Blood Cells, Mol. Dis., 27(4):728-730 (2001).
Iwaki, D., et al., “The Extracellular Toll-Like Receptor 2 Domain Directly Binds Peptidoglycan Derived fromStaphylococcus aureus,” J. Biol. Chem., 277(27):24315-24320 (2002).
Kirschning, C.J., et al., Human Toll-Like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide,J. Exp. Med., 188(11):2091-2097 (1998).
Li, M., et al., “An Essential Role of the NF-xB/Toll-Like Receptor Pathway in Induction of Inflammatory and Tissue-Repair Gene Expression by Necrotic Cells,”J. Immunol., 166:7128-7135 (2001).
Martin, M., et al., “Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A,”Infect. Immun., 71(5):2498-2507 (2003).
Opal, S.M. and Huber, C.E., “Bench-To-Bedside Review: Toll-Like Receptors and Their Role in Septic Shock,”Crit. Care, 6(2):125-136 (2002).
Riedemann, N.C., et al., “Novel Strategies for the Treatment of Sepsis,”Nature Med., 9(5):517-524 (2003).
Scaffidi, P., et al., “Release of Chromatin Protein HMGB1 by Necrotic Cells Triggers Inflammation,”Nature, 418:191-195 (2002).
Yang, R-B., et al., “Signaling Events Induced by Lipopolysaccharide-Activated Toll-Like Receptor 2,”J. Immunol., 163:639-643 (1999).
Yang, R-B., et al., “Toll-Like Receptor-2 Mediates Lipopolysaccharide-Induced Cellular Signalling,”Nature, 395:284-288 (1998).
Zuany-Amorim, C., et al., “Toll-Like Receptors as Potential Therapeutic Targets for Multiple Diseases,”Nat. Rev. Drug Discov., 1:797-807 (2002).
Falciola, L., et al., “High Mobility Group 1 Protein is not Stably Associated with the Chromosomes of Somatic Cells,”J Cell Biol. 137(1):19-26 (1997).
Sparatore, B., et al., “Extracellular High-Mobility Group 1 Protein is Essential for Murine Erythroleukaemia Cell Differentiation,”Biochem. J. 320:253-256 (1996).
Freeman, B. D., et al., “The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies.” inInflammation: Basis Principals and Clinical Correlates(John I. Gallin and Ralph Snyderman eds., Lippincott, Williams & Wilkins, Philadelphia, 3rded. 1999), pp. 965-975.
Abaza, M.-S. I. and Atassi, M. Z., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J Protein Chem. 11(5):433-444 (1992).
Lederman, S., et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4,”Mol Immunol. 28(11):1171-1181 (1991).
Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”Res. Immunol. 145(1):33-36 (1994).
Imamura, T., et al., “Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein,”J. Biol. Chem., 276(10):7534-7540 (2001).
Tsuda, K., et al., “Primary Structure of Non-Histone Protein HMG1 Revealed by the Nucleotide Sequence,”Biochemistry, 27:6159-6163 (1988).
Meng, G., et al., “Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes,”J. Clin. Invest., 113(1):1473-1481 (2004).
Patel, M., et al., “TLR2 Agonist Ameliorates Established Allergic Airway Inflammation by Promoting Th1 Response and Not via Regulatory T Cells1,”J. Immunol, 174:7558-7563 (2005).
Meng, G., et al., “Murine TLR2 expression anaylsis and systemic antagonism by usage of specific monoclonal antibodies,”Immunology Letters, 98:200-207, (2005).
Yakushijin, T., et al., “Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection,”Hepatology Research, 34:156-162 (2006).
Tracey Kevin J.
Yang Huan
Hamilton Brook Smith & Reynolds P.C.
Kam Chih-Min
The Feinstein Institute for Medical Research
LandOfFree
Inhibitors of the interaction between HMGB polypeptides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the interaction between HMGB polypeptides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the interaction between HMGB polypeptides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3766693